Fortress Biotech
FBIO
79 hedge funds and large institutions have $48.3M invested in Fortress Biotech in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 28 reducing their positions, and 10 closing their positions.
0.11% more ownership
Funds ownership: 2.16% → 2.27% (+0.11%)
4% less funds holding
Funds holding: 82 → 79 (-3)
14% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 28
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
24% less call options, than puts
Call options by funds: $159K | Put options by funds: $208K
40% less capital invested
Capital invested by funds: $81.1M → $48.3M (-$32.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$4.29M |
| 2 |
Renaissance Technologies
New York
|
+$1.83M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$487K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$372K |
| 5 |
CL
CPWM LLC
Seattle,
Washington
|
+$269K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$444K |
| 2 |
Man Group
London,
United Kingdom
|
-$227K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$219K |
| 4 |
Barclays
London,
United Kingdom
|
-$143K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$138K |
FBIO Hedge Fund Activity: Q1 2022 in Review
79 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q1 2022, worth a combined $48.3M — down 40% from $81.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of FBIO and 8 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 24 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $4.29M. The largest seller was Nantahala Capital Management, cutting an estimated $444K.
- 79 institutional investors held Fortress Biotech (FBIO) as of Q1 2022, down from 82 in Q4 2021.
- Funds reported $48.3M of Fortress Biotech stock for Q1 2022, down 40% quarter-over-quarter.
- 8 funds opened new Fortress Biotech positions in Q1 2022 and 10 closed out, a net change of -2 holders.
- The largest Fortress Biotech buyer in Q1 2022 was Tang Capital Management, an estimated $4.29M added.
- The largest Fortress Biotech seller in Q1 2022 was Nantahala Capital Management, an estimated $444K sold.
Based on aggregated 13F filings for Q1 2022.